Potential Antiretroviral Drug Interactions With Cyclophosphamide, Doxorubicin, and Etoposide

This publication has 13 references indexed in Scilit:

• Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin’s Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494)
  Journal of Clinical Oncology, 2004
• Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma
  AIDS, 2002
• Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
  AIDS, 2002
• Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
  The Lancet, 2002
• Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV Infection
  Clinical Pharmacokinetics, 2002
• Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy
  Journal of Clinical Oncology, 2001
• Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors
  Clinical Pharmacokinetics, 2001
• Dose-Adjusted EPOCH Chemotherapy (CT) in Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma (HIV-NHL): Preliminary Report of Efficacy, Immune Reconstitution, and HIV Control Following Therapy.
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
• Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma
  Medical Oncology, 1998
• The Effects of Antineoplastic Chemotherapy on HIV Disease
  AIDS Research and Human Retroviruses, 1996